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Abstract 
Background: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by 
thrombosis, fetal losses and thrombocytopenia associated to antiphospholipid (APL) antibodies 
(Abs). They are directed to phospholipids, such as cardiolipins (a-cardiolipin, ACA) and lupus 
anticoagulant (LA), or to complexes formed by phospholipids and protein cofactors, such as β2 
glycoprotein 1 (a-β2GP1) and annexin V (a-annexin V). These auto Abs may be considered as a 
family of Abs involved in thrombotic events and APL activity. On the other hand, some 
proangiogenic factors are involved in the normal development of placental vasculature, such as the 
vascular endothelial growth factor (VEGF). Overexpression of VEGF receptor in its soluble form 
(sVEGFR-1) has been associated to a higher antiangiogenic activity. Our aim was to analyze the 
association between ACA, LA, a-β2GP1, a-annexin V and sVEGFR-1 with recurrent miscarriage 
before week 10 of gestation in women with APS. Methods: We studied 24 women (primary or 
secondary APS), who were divided into two groups: women with recurrent miscarriage before week 
10 of gestation [M; n=12] and women with no history of fetal loss [NM; n=12]. ACA, a-β2GP1, a-
annexin V and sVEGF-R1 levels were assessed by ELISA, while LA was assessed by screening 
and confirmatory tests. Results: A significant association was observed between the number of 
positive biomarkers and the belonging group (p<0.05). Besides, a positive result for LA and a-
β2GP1 was found to be significantly associated to the M group (p<0.05). Conclusions: LA and a-
β2GP1 may be implicated in pregnancies complicated by recurrent miscarriage in women with APS. 
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1. Introduction 
Antiphospholipid (APL) antibodies (Abs) constitute a heterogeneous group of Abs that can appear 
associated to autoimmune diseases, infectious diseases, cancer and some lupus-inducing drugs. 
The probability of miscarriage in patients bearing these Abs, without treatment, is of 91% [1] and 
those pregnancies that do not have an abortion outcome, have a higher risk of preeclampsia, low 
weight of the newly born, prematurity and fetal distress [2]. Although placental thrombotic events 
may play an important role [3], it is nowadays assumed that non-thrombotic mechanisms would be 
the main cause for the defective placentation observed in patients with antiphospholipid syndrome 
(APS) [4-6].  APS is an autoimmune disease characterized by arterial/venous thrombosis and/or 
obstetric complications, associated to the persistent presence of anticardiolipins (ACA) and/or lupus 
anticoagulant (LA) and/or anti-2 glycoprotein 1(a-2GP1) [7]. APS is either a primary disease or it 
can be associated to another autoimmune disease, such as systemic lupus erythematosus (SLE). 
For the diagnosis of APS it is required: the presence of moderate/high levels of ACA; the presence 
of LA; the presence of a-2GP1 higher than percentile 99, together with a clinical event of vascular 
thrombosis or pregnancy complications. APS is present if at least one of the clinical criteria and one 
of the laboratory criteria (on 2 or more occasions, at least 12 weeks apart) are met [8,9,10]. 
In 1990 it was reported that the main antigenic target of APL Abs is β2GP1; consequently, the study 
of this protein in the pathogenesis of APS became of great interest for the scientific community [11]. 
Among the known cofactors, β2GP1 is the most studied, since it would play an anticoagulant role in 
vivo; the presence of Abs against this molecule would interfere with its normal physiological 
function. β2GP1 is a highly glycosylated polypeptidic chain with 5 domains: domain I reacts with 
APL Abs, while Abs associated to non-APS diseases are directed to domains II to V. The site of 
interaction of β2GP1 with negatively charged phospholipids, such as cardiolipins, 
phosphatidylserine and phosphatidylinositol, is located in domain V. Domain I is normally hidden 
and it is exposed when in contact with membrane phospholipids. When APL Abs bind to endothelial 
cells forming complexes with β2GP1, they induce the activation of such cells, and therefore, the 
initiation of the coagulation process [12]. Evidence also exists for APL Abs to promote platelet 
activation and aggregation via binding of a-β2GP1 complexes to glycoprotein Ib on platelet surface. 
Abs that recognize a cryptic epitope (Gly40-Arg43) in domain I of β2GP1 are closely related to APL 
and strongly correlate with thrombosis and obstetric complications. β2GP1-dependent APL Abs can 
recognize their own antigen on the trophoblast and decidual cells. It has been suggested that 
cellular functions of the trophoblast would be altered, thus leading to defective placentation and 
playing a crucial pathogenic role in obstetric complications in the APS, by non-thrombotic 
mechanisms [5,13-15]. At the same time, the formation of immune complexes a-β2GP1 can 
activate the classical pathway of complement system and induce localized immune damage [16]. It 
has been demonstrated in vitro that binding of a-β2GP1 to the syncytiotrophoblast affects its 
invasive capacity [17] and decreases human chorionic gonadotrophin synthesis [18,19].  
Another cofactor studied in APS is annexin V. Annexins are glycoproteins that bind phospholipids in 
a calcium-dependent manner. They present a wide range of biological actions, including an 
anticoagulant effect. This effect would be explained by their ability to sequester calcium from the 
phospholipid matrix, where it interacts with proteins of the coagulation cascade. Then it would form 
a protective cover that would isolate the apical surface of placental villi from circulating coagulation 
proteins [20]. It has been postulated that displacement of annexin V from the cellular surface by a-
annexin V Abs found in the sera of patients with APS, would be responsible for the generation of a 
thrombogenic environment and the consequent fetal loss [21]. On the other hand, the proper 
development of placental vasculature requires the action of proangiogenic factors, such as vascular 
endothelial growth factor (VEGF), a factor involved in vasculogenesis and angiogenesis. In the 
angiogenesis, VEGF stimulates the survival, proliferation and motility of endothelial cells, thus 
initiating the genesis of a new capillary. This factor is found either soluble in plasma or bound to 
heparin sulphate, depending on the isoform. The surface receptors of VEGF (VEGFR1, 2 and 3) 
are expressed mainly in endothelial cells and placenta [22]. Different studies have clearly 
demonstrated that receptors 1 and 2 are involved in capillary formation and vascular development 
during embryogenesis [23]. The soluble isoform of VEGF R1 (sVEGF R1) retains the ability to bind 
VEGF and forms inactive homo- and heterodimers, thus impeding its binding to the cell surface 
receptor and therefore acting as an inhibitor [24].  
Available data regarding the role of ACA, LA, a-β2GP1, a-annexin V and sVEGF R1 in the recurrent 
miscarriage in women with APS are scarce. Besides, if a-β2GP1 were found to be involved in 
recurrent miscarriage before week 10 of gestation, it would imply the additional utilization of anti-
inflammatory and immunosuppressor drugs in such patients. Therefore, the aim of the present 
study was to analyze the association of ACA, LA, a-β2GP1, a-annexin V and sVEGF R1 with 
miscarriage before week 10 of gestation in women with APS.  
 
2. Methods 
2.1. Patients: A retrospective study was performed. Twenty-four female patients with an established 
diagnosis of APS (either primary or secondary to SLE), according to the International Consensus 
2006 [25] were studied. The APS clinical criterion present in all patients was vascular thrombosis. 
Twelve of these patients also presented 3 or more consecutive unexplainable miscarriages before 
week 10 of gestation, having already excluded maternal anatomical or hormonal abnormalities, as 
well as chromosomal alterations in both parents (group M). The other 12 patients, who had at least 
2 previous normal pregnancies and no history of obstetric complications constituted the control 
group (NM). Patients were classified for SLE according to the criteria of the American College of 
Rheumatology 1997 [26]. Patients were derived from the Rheumatology and Systemic Autoimmune 
Diseases Section of the Hospital J. B. Iturraspe of Santa Fe. Samples used throughout the study 
were obtained during the first trimester of pregnancy. The study was approved by the Bioethics 
Comitee of Facultad de Ciencias Bioquímicas y Farmacéuticas (Universidad Nacional de Rosario), 
and all participants signed the corresponding informed consent. 
 
2.2. Determination of ACA (IgM and IgG): Serum samples were collected and ACA were 
determined by an “in house” ELISA method using cardiolipin from bovine heart as antigen (Sigma, 
St. Louis, USA). Results are expressed as UMPL/ml and UGPL/ml for M and G isotypes, 
respectively. The reference (normal) value obtained in our laboratory was < 10 (either for IgM or 
IgG) and was considered negative. The positive values were classified as: low titer, 10 to 40; 
moderate titer, 40 to 80; high titer, > 80. We considered as positive criterion the finding of values in 
the high and moderate ranges [25]. 
 
2.3. Determination of total a-β2GP1 (IgG, IgA and IgM): Serum samples were collected and total a-
β2GP1 was assessed by a quantitative ELISA (ORG 521S Anti-beta-2-Glycoprotein I Screen, 
Orgentec Diagnostika GmbH Mainz – Germany). The cut off value for our laboratory was 10 U/ml. 
This value was obtained as a result of media ± 3 SD, from serum samples of 50 healthy subjects.  
 
2.4. Determination of a-annexin V (IgG and IgM): Serum samples were collected and determination 
of a-annexin V Ab was performed by means of an “in house” ELISA, utilizing annexin V form human 
placenta as antigen (Sigma, St. Louis, USA). The reference interval for our laboratory was 0 to 6 
U/ml [27]. 
 
2.5. Detection of LA: Study of LA was performed in patients not receiving oral anticoagulants or 
heparin. Samples were collected with sodium citrate as anticoagulant and then, subjected to double 
centrifugation in order to obtain platelet-poor plasma. Protocol for LA study followed the criteria of 
the International Society on Thrombosis and Haemostasis 2009. As screening tests, we used aPTT 
Actin FSL (Siemens, Munich, Germany), PTT-LA (Stago, Asnières-sur-Seine, France), dilute 
Russell's viper venom time dRVVT (Stago, Asnières-sur-Seine, France) and mixtures with normal 
plasma for the determination of correction or no correction of altered tests. In the case of positive 
screening tests, we performed confirmatory tests using reagents with high concentrations of 
phospholipids as the test of neutralization with hexagonal phospholipids Staclot-LA (Stago, 
Asnières-sur-Seine, France). 
 
2.6. Detection of sVEGF R1: Samples were collected with EDTA as anticoagulant. Detection of 
sVEGF R1 was performed using a quantitative ELISA (R&D Systems, Minneapolis, MN, USA). The 
cut off value for our laboratory was 123 pg/ml. This value was obtained as a result of media ± 3 SD, 
from serum samples of 50 non-pregnant healthy subjects.  The cut off value for the first trimester of 
pregnancy was <1453 pg/ml, and it was obtained by processing 30 plasma samples of pregnant 
women with no associated disease and media ± 3 SD was calculated.  
 
2.7. Statistical analysis: Statistical analysis was performed using the Chi square test, the Score 
exact test or the Fisher exact test and odds ratio (OR) estimates and their 95% confidence intervals 
(CI), depending on the case. A p value <0.05 was considered as statistically significant.   
 
3. Results 
APS is an autoimmune disease characterized by thrombosis, fetal losses and thrombocytopenia 
associated to APL Abs. The aim of this study was to analyze the association between ACA, LA, a-
β2GP1, a-annexin V and sVEGFR-1 with recurrent miscarriage before week 10 of gestation in 
women with APS. 
Values obtained for each individual assay for the case of ACA, LA, a-β2GP1, a-annexin V and 
sVEGF R1 are shown in Table 1, and Figure 1 shows the percentage of positive and negative 
results for each parameter in each group of patients studied (M and NM). No significant association 
was found between the group where the patients belonged and ACA, a-annexin V and sVEGF-R1 
(p=0.5; p=0.76 and p=0.5; respectively). In contrast, LA and a-β2GP1 were found to be significantly 
associated to the belonging group (p=0.03 for both variables). By analyzing the number of positive 
biomarkers for each of the groups studied, a significant association with the belonging group was 
observed (p=0.0193). In group M we found a higher number of positive biomarkers as compared to 
group NM (Table 2). Besides, our results show that the chance of belonging to group M for patients 
with positive LA or positive a-β2GP1 is 11.5 times higher than when these parameters are negative 
(Table 3).  
 
4. Discussion  
The mechanism of fetal loss related to the presence of APL Abs is poorly understood yet. Although 
these Ab are directly involved in thrombosis leading to placental infarction and fetal death, 
nowadays other non-thrombotic a-β2GP1-mediated mechanisms have been postulated. The non-
thrombotic hypothesis suggests that binding of these Abs to β2GP1 on the trophoblastic membrane 
would perturb these membranes and alter placentation.    
Decrease in trophoblastic proliferation and growth, and defective placentation, both induce a 
proinflammatory phenotype interfering with physiological implantation [18]. In accordance with our 
results, Sailer et al. [28] reported an association between pregnancy loss and the presence of LA 
and a-β2GP1 Ab. On the other hand, Arnold et al. [29] found no significant differences in a-β2GP1 
Abs between women with recurrent miscarriage with or without APS. Other authors [30] observed 
that the simultaneous presence of ACA, LA and a-β2GP1 Abs confers a higher risk of developing 
severe manifestations of APS. Our results particularly associate the presence of LA and/or a-
β2GP1 Abs, but not that of ACA, with recurrent miscarriage. According to Meroni et al. [7], patients 
with APS should be divided in four categories: category I includes women with more than one 
positive test in any combination, and category II includes those women with only one positive test 
(IIa: positive LA; IIb: positive ACA; and IIc: positive a-β2GP1 Abs). Triple positivity constitutes the 
most predictive profile of clinical manifestations and recurrences despite conventional treatment. 
Our results show a similar behaviour, since group M bears a higher number of positive biomarkers 
than group NM. However, some women with persistent elevated levels of ACA and LA and history 
of thrombotic events do not have fetal complications while, in some cases, women without ACA or 
LA and without a known cause, undergo recurrent miscarriage. Some authors postulate that a-
annexin V Abs would be involved in reproductive failures [31]. Our results are coincident with those 
of Alijotas-Reig et al. [32], who reported that a-annexin V Abs should not be considered as a risk 
factor for miscarriage and inexplicable fetal death. In line with this, Bizzaro et al. [33] conclude that 
a-annexin V Abs determined in healthy women do not bear a predictive value on involuntary 
abortion and that they are not useful to evaluate the risk at the beginning of pregnancy. On the 
other hand, Galli et al. [34] demonstrated that a-annexin V IgG but not those of IgM type are related 
to fetal loss. Although annexin V concentrations are decreased in the placenta of women with 
miscarriage and APL Abs, and although a-annexin V Abs could interfere with the normal function of 
the syncytiotrophoblast, our results are not those expected according to the physiology of annexin V 
and the pathophysiology of a-annexin V Abs. Lastly, different studies have demonstrated that 
placental expression and maternal circulating levels of sVEGFR-1 are elevated in preeclampsia. In 
vitro experiments showed that sVEGFR-1 induces vasoconstriction and endothelial dysfunction; 
therefore this protein would be involved in the interaction between decreased placental perfusion 
and deep maternal endothelial function alteration. In light of these findings [35], we investigated the 
likely association between this parameter and recurrent fetal losses in APS. Our findings in the 
sample studied, would however discard a role for sVEGFR-1 in the recurrent miscarriage in women 
with APS. 
 
5. Conclusion 
Traditionally, ACA and LA have been considered serologic markers of choice in the classification of 
APS, and a-β2GP1 Abs has been recently incorporated as a laboratory criterion. We conclude that 
LA and a-β2GP1 Ab would be good indicators of miscarriage risk in women with APS, thus 
reinforcing the role of a-β2GP1, not only in the diagnosis but also as a likely marker of recurrent 
miscarriage in that disease. The optimal treatment in patients with APS is controversial and it is 
under continuous revision due to the fact that the low number of patients makes it difficult to 
perform adequate prospective studies that allow drawing definitive conclusions. Although the 
association between the presence of APL Ab and thrombosis seems clear, the therapeutic attitude 
should not be primarily directed towards elimination or reduction of the levels of these Abs through 
plasmapheresis, high doses of intravenous immunoglobulins, and immunosuppressors (except in 
catastrophic APS), since a clear correlation does not exist between Ab titers and thrombotic 
episodes. Treatment of these patients is based on the use of platelets antiaggregants and 
anticoagulants aimed to prevent placental thrombotic events that would ultimately lead to 
miscarriage. Nevertheless, the participation of β2GP1-dependent non-thrombotic events that would 
be responsible for the defective placentation observed in APS [4-6], would lead to reformulation of 
the treatment currently applied to these patients. It is worth noting that, although the number of 
patients included in the present study may seem somewhat low, this is due to the fact that we have 
been very strict as regards the inclusion criteria applied, thus partly explaining the amplitude of the 
confidence interval obtained. Recruitment of patients with APS and no history of obstetric 
complications (NM group), and with APS undergoing fetal losses before week 10 (M group), made it 
difficult to gather a larger group of patients.  
Further work investigating the effect of anti-inflammatory and immunosuppressor therapy in patients 
with recurrent miscarriage before week 10 of gestation and persistent positive a-β2GP1 will be 
required for considering these drugs as an alternative therapeutic strategy besides the conventional 
anticoagulant therapy. 
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Figure Legend 
Figure 1. Levels of anti-cardiolipin (ACA), lupus anticoagulant (LA), anti-2 glycoprotein 1 (a-
2GP1), anti-annexin V (a-annexin V), and soluble vascular endothelial growth factor receptor 1 
(sVEGF R1) in women with antiphospholipid syndrome (APS). The following parameters were 
evaluated in women with APS with recurrent miscarriage before week 10 of gestation [M; n=12] and 
with no history of fetal loss [NM; n=12]: a) ACA; b) LA; c) a-2GP1; d) a-annexin V; and e) 
sVEGFR-1. Black and white bars represent the percentage of positive and negative results for each 
parameter, respectively. ACA were considered positive for titers > 40. *p<0.05 vs M. 
   
 
 
 
 Group M 
Patient N° 
ACA UPL/ML 
(IgG/IgM) 
LA (Pos/Neg) 
Total a-β2GP1 
U/ML 
a-annexin V  
U/ML (IgG/IgM) 
sVEGFR-1 
pg/ML 
1 20/<10 Neg <10 <6/<6 490 
2 74/<10 Pos <10 <6/<6 510 
3 62/50 Pos <10 <6/<6 836 
4 <10/72 Neg <10 <6/<6 2112 
5 88/45 Pos <10 <6/<6 740 
6 25/10 Neg 20 <6/<6 957 
7 124/65 Neg 17 <6/<6 631 
8 108/23 Neg 30 <6/<6 950 
9 52/<10 Neg <10 <6/<6 410 
10 20/<10 Pos 15 <6/<6 1024 
11 25/<10 Pos 25 10/2 963 
12 79/45 Pos 35 <6/<6 843 
 
Group NM 
Patient N° 
ACA UPL/ML 
(IgG/IgM) 
LA (Pos/Neg) 
Total a-β2GP1 
U/ML 
a-annexin V  
U/ML (IgG/IgM) 
sVEGFR-1 
pg/ML 
1 45/<10 Neg <10 <6/<6 774 
2 20/<10 Neg <10 <6/<6 415 
3 50/23 Neg <10 <6/<6 989 
4 48/30 Neg <10 <6/<6 476 
5 76/30 Neg <10 <6/<6 1024 
6 44/18 Pos <10 <6/<6 1114 
7 115/26 Neg 25 <6/<6 479 
8 15/<10 Neg <10 <6/<6 1624 
9 25/42 Neg <10 <6/<6 1026 
10 15/<10 Neg <10 8/3 1147 
11 12/<10 Neg <10 <6/<6 782 
12 27/<10 Neg <10 <6/<6 1980 
 
 
Table 1. Relative value of each individual assay in both groups of patients studied. Levels of 
anticardiolipins (ACA), lupus anticoagulant (LA), total anti-2 glycoprotein 1 (a-2GP1), a-annexin V 
and soluble isoform of surface receptors 1 of vascular endothelial growth factor (sVEGF R1) are 
shown for each group of patients. M: patients that presented 3 or more consecutive unexplainable 
miscarriages before week 10 of gestation. NM: patients who had at least 2 previous normal 
pregnancies and no history of obstetric complications.   
 
 
  
 
 Table 2. Number of positive biomarkers in each of the groups of patients studied. The 
number of positive biomarkers in each of the groups of patients studied is shown. A significant 
association was found between the number of positive biomarkers and the belonging group 
(p=0.0193). M: patients that presented 3 or more consecutive unexplainable miscarriages before 
week 10 of gestation. NM: patients who had at least 2 previous normal pregnancies and no history 
of obstetric complications.   
Group No positive 
biomarkers 
One positive 
biomarker 
Two 
positive 
biomarkers 
Three 
positive 
biomarkers 
Four 
positive 
biomarkers 
M 1 0 2 7 2 
NM 2 3 5 2 0 
Total  3 3 7 9 2 
 Table 3. Odds ratios (OR) estimates for lupus anticoagulant (LA) and anti-2 glycoprotein 
1(a-2GP1). OR and their 95% confidence intervals (CI) were evaluated for the variables LA and a-
2GP1, which were significantly associated to the belonging group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable OR (Pos vs. Neg) CI (95%) 
LA 11.5 0.93 ;141.7 
a-2GP1 11.5 0.93 ;141.7 
